AU2017206718B2 - Treatment for tumors driven by metabolic dysfunction - Google Patents

Treatment for tumors driven by metabolic dysfunction Download PDF

Info

Publication number
AU2017206718B2
AU2017206718B2 AU2017206718A AU2017206718A AU2017206718B2 AU 2017206718 B2 AU2017206718 B2 AU 2017206718B2 AU 2017206718 A AU2017206718 A AU 2017206718A AU 2017206718 A AU2017206718 A AU 2017206718A AU 2017206718 B2 AU2017206718 B2 AU 2017206718B2
Authority
AU
Australia
Prior art keywords
cancer
compound
tumor
present disclosure
certain aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017206718A
Other languages
English (en)
Other versions
AU2017206718A1 (en
Inventor
Peter Cornelius
James Shanahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SynDevRX Inc
Original Assignee
SynDevRX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SynDevRX Inc filed Critical SynDevRX Inc
Publication of AU2017206718A1 publication Critical patent/AU2017206718A1/en
Application granted granted Critical
Publication of AU2017206718B2 publication Critical patent/AU2017206718B2/en
Priority to AU2021286420A priority Critical patent/AU2021286420B2/en
Priority to AU2024204027A priority patent/AU2024204027A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017206718A 2016-01-11 2017-01-11 Treatment for tumors driven by metabolic dysfunction Active AU2017206718B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021286420A AU2021286420B2 (en) 2016-01-11 2021-12-17 Treatment for tumors driven by metabolic dysfunction
AU2024204027A AU2024204027A1 (en) 2016-01-11 2024-06-13 Treatment for tumors driven by metabolic dysfunction

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662277293P 2016-01-11 2016-01-11
US62/277,293 2016-01-11
US201662393929P 2016-09-13 2016-09-13
US62/393,929 2016-09-13
US201662395446P 2016-09-16 2016-09-16
US62/395,446 2016-09-16
PCT/US2017/012968 WO2017123603A1 (en) 2016-01-11 2017-01-11 Treatment for tumors driven by metabolic dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021286420A Division AU2021286420B2 (en) 2016-01-11 2021-12-17 Treatment for tumors driven by metabolic dysfunction

Publications (2)

Publication Number Publication Date
AU2017206718A1 AU2017206718A1 (en) 2018-07-05
AU2017206718B2 true AU2017206718B2 (en) 2021-09-30

Family

ID=57882196

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017206718A Active AU2017206718B2 (en) 2016-01-11 2017-01-11 Treatment for tumors driven by metabolic dysfunction
AU2021286420A Active AU2021286420B2 (en) 2016-01-11 2021-12-17 Treatment for tumors driven by metabolic dysfunction
AU2024204027A Pending AU2024204027A1 (en) 2016-01-11 2024-06-13 Treatment for tumors driven by metabolic dysfunction

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021286420A Active AU2021286420B2 (en) 2016-01-11 2021-12-17 Treatment for tumors driven by metabolic dysfunction
AU2024204027A Pending AU2024204027A1 (en) 2016-01-11 2024-06-13 Treatment for tumors driven by metabolic dysfunction

Country Status (9)

Country Link
US (3) US10646463B2 (cg-RX-API-DMAC7.html)
EP (1) EP3402529A1 (cg-RX-API-DMAC7.html)
JP (3) JP7022066B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180100663A (cg-RX-API-DMAC7.html)
CN (2) CN114225045B (cg-RX-API-DMAC7.html)
AU (3) AU2017206718B2 (cg-RX-API-DMAC7.html)
CA (2) CA3008960C (cg-RX-API-DMAC7.html)
MX (2) MX2018008321A (cg-RX-API-DMAC7.html)
WO (1) WO2017123603A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
ES2749746T3 (es) 2013-04-10 2020-03-23 Syndevrx Inc Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN114225045B (zh) 2016-01-11 2025-09-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
SMT202200173T1 (it) 2016-06-01 2022-05-12 Athira Pharma Inc Composti
CN107670048B (zh) 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
AU2019366819C1 (en) * 2018-10-26 2025-12-18 Syndevrx Inc. Biomarkers of MetAP2 inhibitors and applications thereof
CN112915210B (zh) * 2019-12-06 2024-08-20 重庆阿普格雷生物科技有限公司 一种聚乙二醇偶联药物、其制备方法及应用
CN116887836A (zh) * 2020-11-11 2023-10-13 辛德弗雷克斯公司 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合
KR20230117574A (ko) * 2020-11-11 2023-08-08 신데브알엑스, 인크. 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합
AU2023322022A1 (en) * 2022-08-10 2025-02-27 Syndevrx, Inc. Metap2 inhibitors for the treatment of pulmonary fibrosis
WO2024107996A1 (en) * 2022-11-16 2024-05-23 Syndevrx, Inc. Metap2 inhibitors for the treatment of prostate cancer
CN119932197B (zh) * 2025-04-09 2025-06-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150088A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized drug conjugates

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
ES2224465T3 (es) 1997-10-31 2005-03-01 Children's Medical Center Corporation Metodo para regular el tamaño y el crecimiento del tejido normal vascularizado.
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
SK16282000A3 (sk) 1998-05-01 2001-05-10 Abbott Laboratories Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
EP1080732A4 (en) 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
HK1042438A1 (zh) 1998-10-30 2002-08-16 第一制药株式会社 Dds化合物及其测定方法
EP1222217B1 (en) 1999-09-08 2005-06-15 Polytherics Limited Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7087768B2 (en) 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
US20040005641A1 (en) 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7332523B2 (en) 2002-04-11 2008-02-19 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
WO2006084054A2 (en) 2005-02-02 2006-08-10 Children's Medical Center Corporation Method of treating angiogenic diseases
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008331516B2 (en) 2007-11-28 2014-01-09 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CN101896177A (zh) 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
CN102105156B (zh) 2008-05-22 2016-05-25 特拉维夫大学拉莫特有限公司 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
TWI373345B (en) 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
CN102791699B (zh) * 2010-01-08 2016-04-06 扎夫根公司 烟曲霉醇型化合物和其制造和使用方法
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
SMT201900190T1 (it) 2010-11-12 2019-05-10 Pharma Mar Sa Multiterapia con un inibitore mitotico
MX342257B (es) 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
ES2749746T3 (es) 2013-04-10 2020-03-23 Syndevrx Inc Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad
HRP20211879T1 (hr) 2013-08-14 2022-03-04 Novartis Ag Kombinirana terapija za liječenje raka
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN114225045B (zh) 2016-01-11 2025-09-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
WO2018027084A2 (en) 2016-08-03 2018-02-08 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
AU2019366819C1 (en) 2018-10-26 2025-12-18 Syndevrx Inc. Biomarkers of MetAP2 inhibitors and applications thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150088A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized drug conjugates

Also Published As

Publication number Publication date
CN108697807B (zh) 2021-11-26
JP2019501206A (ja) 2019-01-17
CA3008960A1 (en) 2017-07-20
US20210077452A1 (en) 2021-03-18
US11273142B2 (en) 2022-03-15
US20170196830A1 (en) 2017-07-13
AU2021286420B2 (en) 2024-03-14
MX2023002076A (es) 2023-03-17
EP3402529A1 (en) 2018-11-21
CA3239447A1 (en) 2017-07-20
AU2017206718A1 (en) 2018-07-05
MX2018008321A (es) 2018-09-21
CN114225045A (zh) 2022-03-25
US10646463B2 (en) 2020-05-12
US20220280470A1 (en) 2022-09-08
JP2025071236A (ja) 2025-05-02
JP7640481B2 (ja) 2025-03-05
AU2024204027A1 (en) 2024-07-04
JP2022048388A (ja) 2022-03-25
AU2021286420A1 (en) 2022-01-20
JP7022066B2 (ja) 2022-02-17
CA3008960C (en) 2024-07-02
WO2017123603A1 (en) 2017-07-20
KR20180100663A (ko) 2018-09-11
CN108697807A (zh) 2018-10-23
CN114225045B (zh) 2025-09-26

Similar Documents

Publication Publication Date Title
AU2021286420B2 (en) Treatment for tumors driven by metabolic dysfunction
US11739069B2 (en) Modulators of resistant androgen receptor
TW202038951A (zh) 用於治療癌症之醫藥組合
KR102346033B1 (ko) 단백질 타이로신 키나아제 조절인자로서의 ｎ-(3-플루오로벤질)-2-(5-(4-모르폴리노페닐)피리딘-2-일)아세트아미드
JP6918378B2 (ja) ＣａＭＫＩＩ阻害剤及びその使用
AU2019366819A1 (en) Biomarkers of MetAP2 inhibitors and applications thereof
JP2024521048A (ja) Ｓｔｉｎｇシグナル伝達組成物の小分子阻害剤および使用の方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)